Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026)
Jade Biosciences (JBIO) reported Income from Continuing Operations of 40368000.0 for Q1 2026, down 5.76% on a YoY basis from 42835868.56 in Q1 2025, and down 26.57% quarter-over-quarter from 31894000.0 in Q4 2025.
Jade Biosciences (JBIO) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Jade Biosciences has reported Income from Continuing Operations for 7 years, with the latest figure at 40368000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 5.76% year-over-year to 40368000.0; the trailing twelve-month figure through Mar 2026 stood at 123359000.0 (down 22.96% YoY), and the FY2025 full-year result was 178000.0, up 100.26% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 40368000.0, down from 31894000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 45221000.0 in Q4 2023, with the low at 46979000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 15632882.35 across 5 years, with a median of 19025000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 434.4% — and 2025, when it plunged 4254.03%.
- Jade Biosciences' Income from Continuing Operations stood at 27488000.0 in 2022, then soared by 64.51% to 45221000.0 in 2023, then tumbled by 203.89% to 46979000.0 in 2024, then soared by 32.11% to 31894000.0 in 2025, then retreated by 26.57% to 40368000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 40368000.0 (Q1 2026), 31894000.0 (Q4 2025), and 25147000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Jade Biosciences | 973.55 Mn | 973.55 Mn | - | -40.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.37 Mn |
| Dec 31, 2025 | -31.89 Mn |
| Sep 30, 2025 | -25.15 Mn |
| Jun 30, 2025 | -25.95 Mn |
| Mar 31, 2025 | -38.17 Mn |
| Dec 31, 2024 | -46.98 Mn |
| Sep 30, 2024 | -14.58 Mn |
| Jun 30, 2024 | -596,000.00 |
| Mar 31, 2024 | -23.19 Mn |
| Dec 31, 2023 | 45.22 Mn |
| Sep 30, 2023 | -19.56 Mn |
| Jun 30, 2023 | -19.03 Mn |
| Mar 31, 2023 | -16.52 Mn |
| Dec 31, 2022 | 27.49 Mn |
| Sep 30, 2022 | -13.59 Mn |
| Jun 30, 2022 | -11.99 Mn |
| Mar 31, 2022 | -10.91 Mn |
| Dec 31, 2021 | -8.22 Mn |
| Sep 30, 2021 | -6.18 Mn |
| Jun 30, 2021 | -5.78 Mn |